Should I buy or sell Trevena stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVN shares. View TRVN analyst ratings or view top-rated stocks .

What is Trevena's stock price target for 2024?

2 brokerages have issued 1 year price objectives for Trevena's stock. Their TRVN share price targets range from $2.00 to $9.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 661.7% from the stock's current price. View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts .

How have TRVN shares performed in 2023?

Trevena's stock was trading at $1.43 at the start of the year. Since then, TRVN stock has decreased by 49.5% and is now trading at $0.7221. View the best growth stocks for 2023 here .

When is Trevena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our TRVN earnings forecast .

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.18 million for the quarter.

When did Trevena's stock split?

Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , SCYNEXIS (SCYX) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Aeterna Zentaris (AEZS) , Bionano Genomics (BNGO) and Dynavax Technologies (DVAX) .

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TRVN

Trevena (TRVN) Stock Price, News & Analysis

$0.72

+0.01 (+1.40%)

(As of 12/29/2023 ET)

Compare

Today's Range: $0.70
▼
$0.74
50-Day Range: $0.52
▼
$0.72
52-Week Range: $0.51
▼
$3.28

Volume: 69,939 shs
Average Volume: 143,721 shs
Market Capitalization: $10.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Trevena MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 661.7% Upside
$5.50 Price Target
Short Interest: Healthy
2.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.70
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

544th out of 950 stocks

Pharmaceutical Preparations Industry

257th out of 442 stocks

3.5

Analyst's Opinion

Consensus Rating
Trevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Trevena has a forecasted upside of 661.7% from its current price of $0.72.
Amount of Analyst Coverage
Trevena has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.10% of the float of Trevena has been sold short.
Short Interest Ratio / Days to Cover
Trevena has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Trevena has recently decreased by 41.83%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Trevena does not currently pay a dividend.
Dividend Growth
Trevena does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRVN.

2.1

News and Social Media Coverage

News Sentiment
Trevena has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Trevena this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for TRVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Trevena to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevena insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Trevena is held by insiders.
Percentage Held by Institutions
Only 4.95% of the stock of Trevena is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Trevena is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevena is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trevena has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Trevena Stock (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

TRVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TRVN Stock News Headlines

December 28, 2023 | finance.yahoo.com

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

December 28, 2023 | finance.yahoo.com

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 27, 2023 | msn.com

Trevena announces private placement and warrant exercise

December 27, 2023 | markets.businessinsider.com

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

December 27, 2023 | finance.yahoo.com

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

December 25, 2023 | americanbankingnews.com

Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

December 16, 2023 | msn.com

Frank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’

December 31, 2023 | Behind the Markets (Ad)

FINAL OFFER: $9 for a FULL YEAR of stock picks

We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?

December 15, 2023 | msn.com

Frank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'

December 4, 2023 | finance.yahoo.com

Trevena Awarded OLINVYK Agreement with Premier, Inc.

December 4, 2023 | finance.yahoo.com

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

November 30, 2023 | finance.yahoo.com

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

November 17, 2023 | finance.yahoo.com

Trevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

November 15, 2023 | finance.yahoo.com

Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript

November 14, 2023 | finanznachrichten.de

Trevena, Inc.: Trevena Reports Third Quarter 2023 Results and Provides Business Update

November 14, 2023 | markets.businessinsider.com

Trevena Reports Third Quarter 2023 Results and Provides Business Update

November 9, 2023 | finance.yahoo.com

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

October 16, 2023 | finance.yahoo.com

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

October 2, 2023 | finance.yahoo.com

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

September 13, 2023 | fool.com

Trevena (NASDAQ: TRVN)

September 8, 2023 | bizjournals.com

Lab Notes: Trevena gets $15M triggered by first sale of drug in China; Braeburn launches opioid use disorder drug Brixadi

September 6, 2023 | marketwatch.com

Trevena Shares Rise 18% After Getting $15M Tranche

September 6, 2023 | theglobeandmail.com

Biotech Shares Are Running Again!

September 6, 2023 | benzinga.com

Why Is Neurology Focused Trevena Stock Trading Higher Today?

September 6, 2023 | msn.com

Trevena gets $15M tranche after first commercial sale of OLINVYK in China

September 6, 2023 | finance.yahoo.com

Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement

See More Headlines

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TRVN
CUSIP: N/A
CIK: 1429560
Web: www.trevena.com
Phone: (610) 354-8840
Fax: N/A
Employees: 35
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $9.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +661.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,670,000.00
Net Margins: N/A
Pretax Margin: -949.98%
Return on Equity: -314.87%
Return on Assets: -71.98%

Debt

Debt-to-Equity Ratio: 8.35
Current Ratio: 6.41
Quick Ratio: 6.27

Sales & Book Value

Annual Sales: $570,000.00
Price / Sales: 19.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.25 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 15,170,000
Free Float: 14,673,000
Market Cap: $10.95 million
Optionable: Optionable
Beta: 1.79

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Ms. Carrie L. Bourdow (Age 60)
President, CEO & Chairman
Comp: $1M
Mr. Barry Shin (Age 51)
Senior VP & CFO
Comp: $670.02k
Dr. Mark A. Demitrack (Age 65)
Senior VP & Chief Medical Officer
Comp: $690.32k
Dr. Howard A. Rockman M.D.
Scientific Founder, Consultant and Member of Scientific Advisory Board
Mr. Joel Solomon
VP, General Counsel & Chief Compliance Officer
Mr. Michael Catalano
Vice President of Marketing
Mr. Robert T. Yoder (Age 57)
Senior VP, Chief Business Officer & Head of Commercial Operations
Comp: $490.64k
Ms. Patricia M. Drake (Age 57)
Senior VP & Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

Jump Financial LLC
Bought 44,396 shares on 11/7/2023
Ownership: 0.324%

View All Institutional Transactions

TRVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevena stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings or view top-rated stocks.
What is Trevena's stock price target for 2024?: 2 brokerages have issued 1 year price objectives for Trevena's stock. Their TRVN share price targets range from $2.00 to $9.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 661.7% from the stock's current price.
View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts.
How have TRVN shares performed in 2023?: Trevena's stock was trading at $1.43 at the start of the year. Since then, TRVN stock has decreased by 49.5% and is now trading at $0.7221.
View the best growth stocks for 2023 here.
When is Trevena's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our TRVN earnings forecast.

How were Trevena's earnings last quarter?: Trevena, Inc. (NASDAQ:TRVN) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.18 million for the quarter.
When did Trevena's stock split?: Shares of Trevena reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Trevena own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).
How do I buy shares of Trevena?: Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVN) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial